The sleep effects of tiagabine on the first night of treatment predict post-traumatic stress disorder response at three weeks.

dc.contributor.author

Krystal, Andrew D

dc.contributor.author

Zhang, Wei

dc.contributor.author

Davidson, Jonathan RT

dc.contributor.author

Connor, Kathryn M

dc.coverage.spatial

United States

dc.date.accessioned

2016-12-01T14:33:08Z

dc.date.issued

2014-05

dc.description.abstract

INTRODUCTION: We sought to test the hypothesis that improvements in sleep might mediate treatment-related improvements in daytime symptoms of post-traumatic stress disorder (PTSD). We evaluated whether changes in sleep occurring on the first night of tiagabine (a gamma-amino butyric acid (GABA) reuptake inhibitor) administration predicted subsequent PTSD response. METHODS: This was an open-label three-week polysomnographic (PSG) study of nightly treatment with tiagabine dosing from 2-12 mg including 20 adults with PTSD with ≥30 min of self-reported and PSG wake time after sleep onset (WASO). RESULTS: A treatment night 1 decrease in self-reported and PSG WASO and an increase in slow-wave sleep (SWS) accounted for 94% of the variance in week 3 Short PTSD Rating Interview (SPRINT) score, the primary outcome measure (p<0.001). Increased night 1 SWS also accounted for 91% of the variance in Work/School Impairment and 45% of the variance in Social Life Impairment as measured with the Sheehan Disability Scale (p<0.001). These relationships were much stronger correlates of three-week outcome than three-week sleep effects. CONCLUSIONS: The initial sleep response to tiagabine may mediate or be an indicator of the subsequent PTSD response. The findings highlight the importance of sleep maintenance and SWS in the treatment of PTSD and also suggest a potential relationship between SWS and daytime function.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/24288237

dc.identifier

0269881113509903

dc.identifier.eissn

1461-7285

dc.identifier.uri

https://hdl.handle.net/10161/13045

dc.language

eng

dc.publisher

SAGE Publications

dc.relation.ispartof

J Psychopharmacol

dc.relation.isversionof

10.1177/0269881113509903

dc.subject

Sleep

dc.subject

post-traumatic stress disorder

dc.subject

tiagabine

dc.subject

Adult

dc.subject

Female

dc.subject

Humans

dc.subject

Male

dc.subject

Neurotransmitter Uptake Inhibitors

dc.subject

Nipecotic Acids

dc.subject

Polysomnography

dc.subject

Sleep

dc.subject

Stress Disorders, Post-Traumatic

dc.title

The sleep effects of tiagabine on the first night of treatment predict post-traumatic stress disorder response at three weeks.

dc.type

Journal article

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/24288237

pubs.begin-page

457

pubs.end-page

465

pubs.issue

5

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Psychiatry & Behavioral Sciences

pubs.organisational-group

Psychiatry & Behavioral Sciences, Brain Stimulation and Neurophysiology

pubs.organisational-group

Psychiatry & Behavioral Sciences, General Psychiatry

pubs.organisational-group

Psychiatry & Behavioral Sciences, Translational Neuroscience

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

28

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
JPsychopharmacol - Krystal 2014 - Tiagabine PTSD.pdf
Size:
406.85 KB
Format:
Adobe Portable Document Format